Ignite Creation Date:
2024-05-06 @ 3:06 PM
Last Modification Date:
2024-10-26 @ 1:43 PM
Study NCT ID:
NCT04524689
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2024-05-17
First Post:
2020-08-20
Brief Title:
Tusamitamab Ravtansine SAR408701 in Combination With Pembrolizumab and Tusamitamab Ravtansine SAR408701 in Combination With Pembrolizumab and Platinum-based Chemotherapy With or Without Pemetrexed in Patients With NSQ NSCLC
Sponsor:
Sanofi
Organization:
Sanofi
Organization Data
Organization:
Sanofi
Class:
INDUSTRY
Study ID:
ACT16146
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Sanofi
Lead Sponsor Class:
INDUSTRY
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None